Table 1 Genes that were stably and consistently dysregulated in 386 cases of hepatocellular carcinoma compared with 327 cases of normal liver tissues according to four independent microarrays retrieved from the Oncomine database, and their associations with hepatocellular carcinoma

TBCE ^b

Up

-

-

INTS8 ^b

Up

-

-

UBAP2L ^b

Up

-

-

GMNN ^b

Up

1

Potential oncogene [38]

UBE2C

Up

4

Cancer progression and poor prognosis [39]

PTTG1

Up

9

Angiogenesis, progression, and poor prognosis [40, 41], therapeutic target [42]

CAP2

Up

10

Multistage hepatocarcinogenesis [43], early detection [44]

TOP2A

Up

11

Early age onset, shorter patient survival and chemoresistance [45]

GPC3

Up

199

Diagnosis [29], cell proliferation and invasion [28]; prediction of recurrence [30]

VIPR1 ^b

Down

-

-

CLEC4M ^b

Down

-

-

MARCO ^b

Down

-

-

DNASE1L3 ^b

Down

-

-

PAMR1 ^b

Down

-

-

ACSM3 ^b

Down

-

-

CLEC1B ^b

Down

1

Downregulated in a cohort of 65 pairs of human HCCs [46]

MT1F ^b

Down

1

Inhibition of cancer growth [47]

CRHBP ^b

Down

1

Downregulated in a cohort of 65 pairs of human HCCs [46]

LCAT ^b

Down

1

LCAT activity correlated with serum albumin and serum bilirubin level [48]

MT1X ^b

Down

1

HCC-related [49]

SRPX ^b

Down

1

Proliferation, migration and invasiveness [50]

MT1H ^b

Down

1

Potential tumour suppressor [51]

FCN2 ^b

Down

2

HBV- and HCV-related HCC [52], FCN2 haplotypes associate with HCC [53]

CXCL14 ^b

Down

4

Potential diagnostic marker [54]; rs2237062 polymorphism influences HBV-related HCC progression [52, 55]; potential tumour suppressor [56]

MT1G ^b

Down

4

Tumour suppressor gene [51, 57], biomarker [58]

EGR1

Down

12

Critical for hepatocarcinogenesis [59]

NAT2

Down

14

NAT2 polymorphism is risk factor for developing HCC [60], NAT2 activity is critical in smoking-related hepatocarcinogenesis [61]